Q-omics provides the consensus-scored IKBKG profile across patient tissues and cancer cell-line models. IKBKG expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, IKBKG is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, IKBKG RNA expression shows 18,923 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, HNSC, and ACC as cancer lineages where IKBKG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IKBKG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IKBKG survival associations across molecular data types. IKBKG RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IKBKG RNA expression–survival associations across cancer types. High IKBKG expression shows unfavorable associations in COAD, LGG and KIRC, but favorable associations in SCLC, SKCM and PAAD. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for IKBKG RNA expression.
This table summarizes IKBKG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IKBKG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IKBKG shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, KIRP and CHOL. The HNSC box plot shows higher IKBKG RNA expression in tumor versus normal tissue (log2 FC = +1.083, t-test p < 0.001).
This table shows molecular features associated with IKBKG in patient tissues and cancer cell lines. In patient samples, IKBKG shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, IKBKG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
